Advertisement

Eligibility criteria for Menopausal Hormone Therapy (MHT): a position statement from a consortium of scientific societies for the use of MHT in women with medical conditions. MHT Eligibility Criteria Group

      Highlights

      • The objective of this project is to create eligibility criteria for the use of menopausal hormone therapy.
      • This will provide a powerful decision-making tool for managing menopausal symptoms.

      Abstract

      This project aims to develop eligibility criteria for menopausal hormone therapy (MHT). The tool should be similar to those already established for contraception A consortium of scientific societies coordinated by the Spanish Menopause Society met to formulate recommendations for the use of MHT by women with medical conditions based on the best available evidence. The project was developed in two phases. As a first step, we conducted 14 systematic reviews and 32 metanalyses on the safety of MHT (in nine areas: age, time of menopause onset, treatment duration, women with thrombotic risk, women with a personal history of cardiovascular disease, women with metabolic syndrome, women with gastrointestinal diseases, survivors of breast cancer or of other cancers, and women who smoke) and on the most relevant pharmacological interactions with MHT. These systematic reviews and metanalyses helped inform a structured process in which a panel of experts defined the eligibility criteria according to a specific framework, which facilitated the discussion and development process. To unify the proposal, the following eligibility criteria have been defined in accordance with the WHO international nomenclature for the different alternatives for MHT (category 1, no restriction on the use of MHT; category 2, the benefits outweigh the risks; category 3, the risks generally outweigh the benefits; category 4, MHT should not be used). Quality was classified as high, moderate, low or very low, based on several factors (including risk of bias, inaccuracy, inconsistency, lack of directionality and publication bias). When no direct evidence was identified, but plausibility, clinical experience or indirect evidence were available, "Expert opinion" was categorized. For the first time, a set of eligibility criteria, based on clinical evidence and developed according to the most rigorous methodological tools, has been defined. This will provide health professionals with a powerful decision-making tool that can be used to manage menopausal symptoms.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Maturitas
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • de Villiers T.J.
        • Hall J.E.
        • Pinkerton J.V.
        • Pérez S.C.
        • Rees M.
        • Yang C.
        • Pierroz D.D.
        Revised global consensus statement on menopausal hormone therapy.
        Maturitas. 2016; 91: 153-155
        • Lambrinoudaki I.
        • Armeni E.
        • Goulis D.
        • Bretz S.
        • Ceausu I.
        • Durmusoglu F.
        • Erkkola R.
        • Fistonic I.
        • Gambacciani M.
        • Geukes M.
        • Hamoda H.
        • Hartley C.
        • Hirschberg A.L.
        • Meczekalski B.
        • Mendoza N.
        • Mueck A.
        • Smetnik A.
        • Stute P.
        • van Trotsenburg M.
        • Rees M.
        Menopause, wellbeing and health: a care pathway from the European Menopause and Andropause Society.
        Maturitas. 2022; 163: 1-14
        • Baber R.J.
        • Panay N.
        • Fenton A.
        • IMS Writing Group
        IMS Recommendations on women’s midlife health and menopause hormone therapy.
        Climacteric 2016. 2016; 19: 109-150
        • The
        hormone therapy position statement of The North American Menopause Society.
        Menopause 2018. 2017; 25: 1362-1387
      1. 4th ed Medical Eligibility Criteria for Contraceptive Use: A WHO Family Planning Cornerstone. World Health Organization, Geneva2010 (PMID: 23741782)
        • Mendoza N.
        • Ramírez I.
        • De la Viuda E.
        • Vázquez J.C.
        • Solà I.
        • Cano A on belhaf of the “HMT Elegibility Criteria Group”
        Eligibility criteria for Menopausal Hormone Therapy (MHT): a consortium of scientific societies for the use of MHT in women with medical conditions. Research protocol.
        Maturitas. 2021 Jun; 148: 14-17
      2. Higgins J.P.T. Thomas J. Chandler J. Cumpston M. Li T. Page M.J. Welch V.A. Cochrane Handbook for Systematic Reviews of Interventions. 2nd edition. John Wiley & Sons, Chichester (UK)2019
        • Moher D.
        • Liberati A.
        • Tetzlaff J.
        • Altman D.G.
        • PRISMA Group
        Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement.
        PLoS Med. 2009; 6 (PMID: 19621072)e1000097https://doi.org/10.1371/journal.pmed.1000097
        • Sterne J.A.
        • Hernán M.A.
        • Reeves B.C.
        • Savović J.
        • Berkman N.D.
        • Viswanathan M.
        • Henry D.
        • Altman D.G.
        • Ansari M.T.
        • Boutron I.
        • Carpenter J.R.
        • Chan A.W.
        • Churchill R.
        • Deeks J.J.
        • Hróbjartsson A.
        • Kirkham J.
        • Jüni P.
        • Loke Y.K.
        • Pigott T.D.
        • Ramsay C.R.
        • Regidor D.
        • Rothstein H.R.
        • Sandhu L.
        • Santaguida P.L.
        • Schünemann H.J.
        • Shea B.
        • Shrier I.
        • Tugwell P.
        • Turner L.
        • Valentine J.C.
        • Waddington H.
        • Waters E.
        • Wells G.A.
        • Whiting P.F.
        • Higgins J.P.
        ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions.
        BMJ. 2016; 355i4919
        • Guyatt G.H.
        • Oxman A.D.
        • Santesso N.
        • Helfand M.
        • Vist G.
        • Kunz R.
        • Brozek J.
        • Norris S.
        • Meerpohl J.
        • Djulbegovic B.
        • Alonso-Coello P.
        • Post P.N.
        • Busse J.W.
        • Glasziou P.
        • Christensen R.
        • Schünemann H.J.
        GRADE guidelines: 12. Preparing summary of findings tables-binary outcomes.
        J. Clin. Epidemiol. 2013; 66: 158-172
        • Manager (RevMan) [Computer program]
        Version 5.4, The Cochrane Collaboration.
        2020
        • Schünemann H.
        • Brożek J.
        • Guyyat G.
        • Oxman A.
        Handbook for grading the quality of evidence and the strength of recommendations using the GRADE approach.
        (Updated October 2013. Available from)
        • Alonso-Coello P.
        • Schünemann H.J.
        • Moberg J.
        • Brignardello-Petersen R.
        • Akl E.A.
        • Davoli M.
        • et al.
        GRADE Evidence to Decision (EtD) frameworks: a systematic and transparent approach to 12 www.eurosurveillance.org making well informed healthcare choices. 1: Introduction.
        BMJ. 2016; 353 (PMID: 27353417)i2016https://doi.org/10.1136/bmj.i2016
        • Chlebowski R.T.
        • Anderson G.L.
        • Gass M.
        • Lane D.S.
        • Aragaki A.K.
        • Kuller L.H.
        • Manson J.E.
        • Stefanick M.L.
        • Ockene J.
        • Sarto G.E.
        • Johnson K.C.
        • Wactawski-Wende J.
        • Ravdin P.M.
        • Schenken R.
        • Hendrix S.L.
        • Rajkovic A.
        • Rohan T.E.
        • Yasmeen S.
        • Prentice R.L.
        • WHI Investigators
        Estrogen plus progestin and BREAST CANCER incidence and mortality in postmenopausal women.
        JAMA. 2010 Oct 20; 304: 1684-1692https://doi.org/10.1001/jama.2010.1500
        • Anderson G.L.
        • Chlebowski R.T.
        • Aragaki A.K.
        • Kuller L.H.
        • Manson J.E.
        • Gass M.
        • Bluhm E.
        • Connelly S.
        • Hubbell F.A.
        • Lane D.
        • Martin L.
        • Ockene J.
        • Rohan T.
        • Schenken R.
        • Wactawski-Wende J.
        Conjugated equine oestrogen and BREAST CANCER incidence and mortality in postmenopausal women with hysterectomy: extended follow-up of the Women’s Health Initiative randomised placebo-controlled trial.
        Lancet Oncol. 2012 May; 13: 476-486https://doi.org/10.1016/S1470-2045(12)70075-X
        • Manson J.E.
        • Chlebowski R.T.
        • Stefanick M.L.
        • Aragaki A.K.
        • Rossouw J.E.
        • Prentice R.L.
        • Anderson G.
        • Howard B.V.
        • Thomson C.A.
        • LaCroix A.Z.
        • Wactawski-Wende J.
        • Jackson R.D.
        • Limacher M.
        • Margolis K.L.
        • Wassertheil-Smoller S.
        • Beresford S.A.
        • Cauley J.A.
        • Eaton C.B.
        • Gass M.
        • Hsia J.
        • Johnson K.C.
        • Kooperberg C.
        • Kuller L.H.
        • Lewis C.E.
        • Liu S.
        • Martin L.W.
        • Ockene J.K.
        • O’Sullivan M.J.
        • Powell L.H.
        • Simon M.S.
        • Van Horn L.
        • Vitolins M.Z.
        • Wallace R.B.
        Menopausal hormone therapy and health outcomes during the intervention and extended post-stopping phases of the Women’s Health Initiative randomized trials.
        JAMA. 2013 Oct 2; 310: 1353-1368https://doi.org/10.1001/jama.2013.278040
        • Manson J.E.
        • Aragaki A.K.
        • Rossouw J.E.
        • Anderson G.L.
        • Prentice R.L.
        • LaCroix A.Z.
        • Chlebowski R.T.
        • Howard B.V.
        • Thomson C.A.
        • Margolis K.L.
        • Lewis C.E.
        • Stefanick M.L.
        • Jackson R.D.
        • Johnson K.C.
        • Martin L.W.
        • Shumaker S.A.
        • Espeland M.A.
        • Wactawski-Wende J.
        • WHI Investigators
        Menopausal hormone therapy and long-term all-cause and cause-specific mortality: the Women’s Health Initiative Randomized Trials.
        JAMA. 2017 Sep 12; 318: 927-938https://doi.org/10.1001/jama.2017.11217
        • Nudy M.
        • Chinchilli V.M.
        • Foy A.J.
        A systematic review and meta-regression analysis to examine the ‘timing hypothesis’ of hormone replacement therapy on mortality, coronary heart disease, and stroke.
        Int. J. Cardiol. Heart Vasc. 2019 Jan 18; 22: 123-131https://doi.org/10.1016/j.ijcha.2019.01.001
        • Kim J.E.
        • Chang J.H.
        • Jeong M.J.
        • Choi J.
        • Park J.
        • Baek C.
        • Shin A.
        • Park S.M.
        • Kang D.
        • Choi J.Y.
        A systematic review and meta-analysis of effects of menopausal hormone therapy on cardiovascular diseases.
        Sci. Rep. 2020 Nov 26; 10: 20631https://doi.org/10.1038/s41598-020-77534-9
        • Zhu D.
        • Chung H.F.
        • Dobson A.J.
        • Pandeya N.
        • Giles G.G.
        • Bruinsma F.
        • Brunner E.J.
        • Kuh D.
        • Hardy R.
        • Avis N.E.
        • Gold E.B.
        • Derby C.A.
        • Matthews K.A.
        • Cade J.E.
        • Greenwood D.C.
        • Demakakos P.
        • Brown D.E.
        • Sievert L.L.
        • Anderson D.
        • Hayashi K.
        • Lee J.S.
        • Mizunuma H.
        • Tillin T.
        • Simonsen M.K.
        • Adami H.O.
        • Weiderpass E.
        • Mishra G.D.
        Age at natural menopause and risk of incident cardiovascular disease: a pooled analysis of individual patient data.
        Lancet Public Health. 2019 Nov; 4: e553-e564https://doi.org/10.1016/S2468-2667(19)30155-0
        • Vinogradova Y.
        • Coupland C.
        • Hippisley-Cox J.
        Use of hormone replacement therapy and risk of venous thromboembolism: nested case-control studies using the QResearch and CPRD databases.
        BMJ. 2019 Jan 9; 364 (Erratum in: BMJ. 2019 Jan 15;364:l162)k4810https://doi.org/10.1136/bmj.k4810
        • Muka T.
        • Oliver-Williams C.
        • Kunutsor S.
        • Laven J.S.
        • Fauser B.C.
        • Chowdhury R.
        • Kavousi M.
        • Franco O.H.
        Association of age at onset of menopause and time since onset of menopause with cardiovascular outcomes, intermediate vascular traits, and all-cause mortality: a systematic review and meta-analysis.
        JAMA Cardiol. 2016; 1: 767-776https://doi.org/10.1001/jamacardio.2016.2415
        • Vinogradova Y.
        • Coupland C.
        • Hippisley-Cox J.
        Use of hormone replacement therapy and risk of breast cancer: nested case-control studies using the QResearch and CPRD databases.
        BMJ. 2020 Oct 28; 371: m3873https://doi.org/10.1136/bmj.m3873
        • Collaborative Group on Hormonal Factors in breast cancer
        Type and timing of menopausal hormone therapy and breast cancer risk: individual participant meta-analysis of the worldwide epidemiological evidence.
        Lancet. 2019 Sep 28; 394: 1159-1168https://doi.org/10.1016/S0140-6736(19)31709-X
        • Beral V.
        • Gaitskell K.
        • Hermon C.
        • Moser K.
        • Reeves G.
        • Peto R.
        • Collaborative Group On Epidemiological Studies Of Ovarian Cancer
        Menopausal hormone use and ovarian cancer risk: individual participant meta-analysis of 52 epidemiological studies.
        Lancet. 2015 May 9; 385: 1835-1842https://doi.org/10.1016/S0140-6736(14)61687-1
        • Sweetland S.
        • Beral V.
        • Balkwill A.
        • Liu B.
        • Benson V.S.
        • Canonico M.
        • Green J.
        • Reeves G.K.
        • Million Women Study Collaborators
        Venous thromboembolism risk in relation to use of different types of postmenopausal hormone therapy in a large prospective study.
        J. Thromb. Haemost. 2012 Nov; 10: 2277-2286https://doi.org/10.1111/j.1538-7836.2012.04919.x
        • Asie N.
        • Mohammed K.
        • Haydour Q.
        • Gionfriddo M.R.
        • Vargas O.L.
        • Prokop L.J.
        • Faubion S.S.
        • Murad M.H.
        Progesterone vs. synthetic progestins and the risk of breast cancer: a systematic review and meta-analysis.
        Syst. Rev. 2016 Jul 26; 5 (PMID: 27456847; PMCID: PMC4960754): 121https://doi.org/10.1186/s13643-016-0294-5
        • Hoibraaten E.
        • Arnesen H.
        • Larsen S.
        • Wickstrom E.
        • Sandset P.M.
        Increased risk of recurrent venous thromboembolism during hormone replacement therapy: results of the randomized, double blind, placebo-controlled estrogen in venous thromboembolism trial (EVTET).
        Thromb. Haemost. 2000; 84: 961-967
        • Olié V.
        • Plu-Bureau G.
        • Conard J.
        • Horellou M.H.
        • Canonico M.
        • Scarabin P.Y.
        Hormone therapy and recurrence of venous thromboembolism among postmenopausal women.
        Menopause. 2011 May; 18: 488-493
        • Rossouw J.E.
        • Anderson G.L.
        • Prentice R.L.
        • LaCroix A.Z.
        • Kooperberg C.
        • Stefanick M.L.
        • Jackson R.D.
        • Beresford S.A.
        • Howard B.V.
        • Johnson K.C.
        • Kotchen J.M.
        • Ockene J.
        • Writing Group for the Women’s Health Initiative Investigators
        Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women’s Health Initiative randomized controlled trial.
        JAMA. 2002 Jul 17; 288: 321-333
        • Canonico M.
        • Plu-Bureau G.
        • Lowe G.D.
        • Scarabin P.Y.
        Hormone replacement therapy and risk of venous thromboembolism in postmenopausal women: systematic review and meta-analysis.
        BMJ. 2008 May 31; 336 (Epub 2008 May 20. PMID: 18495631; PMCID: PMC2405857): 1227-1231https://doi.org/10.1136/bmj.39555.441944.BE
        • Ohira T.
        • Folsom A.R.
        • Cushman M.
        • White R.H.
        • Hannan P.J.
        • Rosamond W.D.
        • Heckbert S.R.
        Reproductive history, hormone replacement, and incidence of venous thromboembolism: the Longitudinal Investigation of Thromboembolism Etiology.
        Br. J. Haematol. 2010 May; 149 (Epub 2010 Mar 3. PMID: 20230397; PMCID: PMC2864348): 606-612https://doi.org/10.1111/j.1365-2141.2010.08128.x
        • Renoux C.
        • Dell’Aniello S.
        • Suissa S.
        Hormone replacement therapy and the risk of venous thromboembolism: a population-based study.
        J. Thromb. Haemost. 2010 May; 8 (Epub 2010 Mar 4): 979-986https://doi.org/10.1111/j.1538-7836.2010.03839.x
        • Rovinski D.
        • Ramos R.B.
        • Fighera T.M.
        • Casanova G.K.
        • Spritzer P.M.
        Risk of venous thromboembolism events in postmenopausal women using oral versus non-oral hormone therapy: a systematic review and meta-analysis.
        Thromb. Res. 2018 Aug; 168 (Epub 2018 Jun 19): 83-95https://doi.org/10.1016/j.thromres.2018.06.014
        • Herrington D.M.
        • Vittinghoff E.
        • Howard T.D.
        • Major D.A.
        • Owen J.
        • Reboussin D.M.
        • Bowden D.
        • Bittner V.
        • Simon J.A.
        • Grady D.
        • Hulley S.B.
        Factor V Leiden, hormone replacement therapy, and risk of venous thromboembolic events in women with coronary disease.
        Arterioscler. Thromb. Vasc. Biol. 2002 Jun 1; 22: 1012-1017https://doi.org/10.1161/01.atv.0000018301.91721.94
        • Cushman M.
        • Kuller L.H.
        • Prentice R.
        • Rodabough R.J.
        • Psaty B.M.
        • Stafford R.S.
        • Sidney S.
        • Rosendaal F.R.
        • Women’s Health Initiative Investigators
        Estrogen plus progestin and risk of venous thrombosis.
        JAMA. 2004 Oct 6; 292: 1573-1580https://doi.org/10.1001/jama.292.13.1573
        • Lowe G.
        • Woodward M.
        • Vessey M.
        • Rumley A.
        • Gough P.
        • Daly E.
        Thrombotic variables and risk of idiopathic venous thromboembolism in women aged 45-64 years. Relationships to hormone replacement therapy.
        Thromb. Haemost. 2000 Apr; 83: 530-535
        • Rosendaal F.R.
        • Vessey M.
        • Rumley A.
        • Daly E.
        • Woodward M.
        • Helmerhorst F.M.
        • Lowe G.D.
        Hormonal replacement therapy, prothrombotic mutations and the risk of venous thrombosis.
        Br. J. Haematol. 2002 Mar; 116: 851-854https://doi.org/10.1046/j.0007-1048.2002.03356.x
        • Douketis J.D.
        • Julian J.A.
        • Crowther M.A.
        • Kearon C.
        • Bates S.M.
        • Barone M.
        • Piovella F.
        • Middeldorp S.
        • Prandoni P.
        • Johnston M.
        • Costantini L.
        • Ginsberg J.S.
        The effect of prothrombotic blood abnormalities on risk of deep vein thrombosis in users of hormone replacement therapy: a prospective case-control study.
        Clin. Appl. Thromb. Hemost. 2011 Nov-Dec; 17 (Epub 2010 Dec 15): E106-E113https://doi.org/10.1177/1076029610387587
        • Straczek C.
        • Oger E.
        • Yon de Jonage-Canonico M.B.
        • Plu-Bureau G.
        • Conard J.
        • Meyer G.
        • Alhenc-Gelas M.
        • Lévesque H.
        • Trillot N.
        • Barrellier M.T.
        • Wahl D.
        • Emmerich J.
        • Scarabin P.Y.
        • Estrogen and Thromboembolism Risk (ESTHER) Study Group
        Prothrombotic mutations, hormone therapy, and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration.
        Circulation. 2005 Nov 29; 112 (Epub 2005 Nov 21): 3495-3500https://doi.org/10.1161/CIRCULATIONAHA.105.565556
        • Li L.
        • Schulz U.G.
        • Kuker W.
        • Rothwell P.M.
        • Oxford Vascular Study
        Age-specific association of migraine with cryptogenic TIA and stroke: population-based study.
        Neurology. 2015 Oct 27; 85 (Epub 2015 Sep 30): 1444-1451https://doi.org/10.1212/WNL.0000000000002059
        • Nappi R.E.
        • Cagnacci A.
        • Granella F.
        • Piccinini F.
        • Polatti F.
        • Facchinetti F.
        Course of primary headaches during hormone replacement therapy.
        Maturitas. 2001 Apr 20; 38: 157-163https://doi.org/10.1016/s0378-5122(00)00215-2
        • Facchinetti F.
        • Nappi R.E.
        • Tirelli A.
        • Polatti F.
        • Nappi G.
        • Sances G.
        Hormone supplementation differently affects migraine in postmenopausal women.
        Headache. 2002 Oct; 42 (Erratum in: Headache. 2003 Feb;43(2):172. Erratum in: Headache. 2003 Mar;43(3):310. PMID): 924-929https://doi.org/10.1046/j.1526-4610.2002.02215.x
        • Nappi R.E.
        • Sances G.
        • Sommacal A.
        • Detaddei S.
        • Facchinetti F.
        • Cristina S.
        • Polatti F.
        • Nappi G.
        Different effects of tibolone and low-dose EPT in the management of postmenopausal women with primary headaches.
        Menopause. 2006 Sep-Oct; 13: 818-825https://doi.org/10.1097/01.gme.0000227399.53192.f5
      3. Boardman HMP, Hartley L, Eisinga A, Main C, Roqué i Figuls M, Bonfill Cosp X, Gabriel Sanchez R, Knight B. Hormone therapy for preventing cardiovascular disease in post-menopausal women. Cochrane Database Syst. Rev. 2015, Issue 3. Art. No.: CD002229. DOI: https://doi.org/10.1002/14651858.CD002229.pub4.

        • Ouyang P.
        • Tardif J.
        • Herrington D.
        • Stewart K.
        • Thompson P.
        • Walsh M.
        • et al.
        Randomized trial of hormone therapy in women after coronary bypass surgery: evidence of differential effect of hormone therapy on angiographic progression of disease in saphenous vein grafts and native coronary arteries.
        Atherosclerosis. 2006; 189: 375-386
        • Herrington D.M.
        • Reboussin D.M.
        • Bridget Brosnihan K.
        • Sharp P.C.
        • Shumaker S.A.
        • Snyder T.E.
        • et al.
        Effects of estrogen replacement on the progression of coronary-artery atherosclerosis.
        N. Engl. J. Med. 2000; 343 (ERA): 522-529
        • Cherry N.
        • Gilmour K.
        • Hannaford P.
        • Heagerty A.
        • Khan M.A.
        • Kitchener H.
        • McNamee R.
        • Elstein M.
        • Kay C.
        • Seif M.
        • Buckley H.
        • ESPRIT team
        Oestrogen therapy for prevention of reinfarction in postmenopausal women: a randomised placebo controlled trial.
        Lancet. 2002 Dec 21-28; 360: 2001-2008https://doi.org/10.1016/s0140-6736(02)12001-0
        • Bibbins-Domingo K.
        • Lin F.
        • VittinghoK E.
        • Barrett-Connor E.
        • Hulley S.
        • Grady D.
        • et al.
        Effect of hormone therapy on mortality rates among women with heart failure and coronary artery disease.
        Am. J. Cardiol. 2005; 95 (HERS I): 289-291
        • Hsia J.
        • Alderman E.L.
        • Verter J.I.
        • Rogers W.J.
        • Thompson P.
        • Howard B.V.
        • et al.
        Women’s angiographic vitamin and estrogen trial: design and methods.
        Control. Clin. Trials. 2002; 23 (WAVE): 708-727
        • Hodis H.N.
        • Mack W.J.
        • Azen S.P.
        • Lobo R.A.
        • Shoupe D.
        • Mahrer P.R.
        • et al.
        Hormone therapy and the progression of coronary-artery atherosclerosis in postmenopausal women.
        N. Engl. J. Med. 2003; 349 (WELL-HART): 535-545
        • Viscoli C.M.
        • Brass L.M.
        • Kernan W.N.
        • Sarrel P.M.
        • Suissa S.
        • Horwitz R.I.
        A clinical trial of estrogen-replacement therapy after ischemic stroke.
        N. Engl. J. Med. 2001; 345 (WEST): 1243-1249
        • Collins P.
        • Flather M.
        • Lees B.
        • Mister R.
        • Proudler A.
        • Stevenson J.C.
        • WHISP (Women’s Hormone Intervention Secondary Prevention Study) Pilot Study Investigators
        Randomized trial of effects of continuous combined HRT on markers of lipids and coagulation in women with acute coronary syndromes: WHISP Pilot Study.
        Eur. Heart J. 2006; 27 (WHISP): 2046-2053
        • Clarke S.C.
        • Kelleher J.
        • Lloyd-Jones H.
        • Slack M.
        • Schofiel P.M.
        A study of hormone replacement therapy in postmenopausal women with ischaemic heart disease: the Papworth HRT atherosclerosis study.
        BJOG. 2002 Sep; 109: 1056-1062https://doi.org/10.1111/j.1471-0528.2002.01544
        • Berglind I.A.
        • Andersen M.
        • Citarella A.
        • Linder M.
        • Sundström A.
        • Kieler H.
        Hormone therapy and risk of cardiovascular outcomes and mortality in women treated with statins.
        Menopause. 2015 Apr; 22 (PMID: 25335101; PMCID: PMC4470525): 369-376https://doi.org/10.1097/GME.0000000000000345
        • Bretler D.M.
        • Hansen P.R.
        • Lindhardsen J.
        • Ahlehoff O.
        • Andersson C.
        • Jensen T.B.
        • Raunsø J.
        • Torp-Pedersen C.
        • Gislason G.H.
        Hormone replacement therapy and risk of new-onset atrial fibrillation after myocardial infarction–a nationwide cohort study.
        PLoS One. 2012; 7e51580https://doi.org/10.1371/journal.pone.0051580
        • Grodstein F.
        • Manson J.E.
        • Stampfer M.J.
        Postmenopausal hormone use and secondary prevention of coronary events in the nurses’ health study. a prospective, observational study.
        Ann. Intern. Med. 2001; 135: 1-8
      4. Khan MA, Liu MW, Singh D, Pal A, Chio FL, Lawson D, Dean LS. Long-term (three years) effect of estrogen replacement therapy on major adverse cardiac events in postmenopausal women after intracoronary stenting. Am. J. Cardiol. 2000 Aug 1;86(3):330-3. doi: https://doi.org/10.1016/s0002-9149(00)00926-7.

        • Alexander K.P.
        • Newby L.K.
        • Hellkamp A.S.
        • Harrington R.A.
        • Peterson E.D.
        • Kopecky S.
        • Langer A.
        • O’Gara P.
        • O’Connor C.M.
        • Daly R.N.
        • Califf R.M.
        • Khan S.
        • Fuster V.
        Initiation of hormone replacement therapy after acute myocardial infarction is associated with more cardiac events during follow-up.
        J. Am. Coll. Cardiol. 2001 Jul; 38: 1-7https://doi.org/10.1016/s0735-1097(01)01329-8
        • Angeja B.G.
        • Shlipak M.G.
        • Go A.S.
        • Johnston S.C.
        • Frederick P.D.
        • Canto J.G.
        • Barron H.V.
        • Grady D.
        • National Registry of Myocardial Infarction 3 Investigators
        Hormone therapy and the risk of stroke after acute myocardial infarction in postmenopausal women.
        J. Am. Coll. Cardiol. 2001 Nov 1; 38: 1297-1301https://doi.org/10.1016/s0735-1097(01)01551-0
        • Apostolakis S.
        • Sullivan R.M.
        • Olshansky B.
        • Lip G.Y.
        Hormone replacement therapy and adverse outcomes in women with atrial fibrillation: an analysis from the atrial fibrillation follow-up investigation of rhythm management trial.
        Stroke. 2014 Oct; 45: 3076-3079
        • Lindenfeld J.
        • Ghali J.K.
        • Krause-Steinrauf H.J.
        • Khan S.
        • Adams K.
        • Goldman S.
        • Peberdy M.A.
        • Yancy C.
        • Thaneemit-Chen S.
        • Larsen R.L.
        • Young J.
        • Lowes B.
        • Rosenberg Y.D.
        • BEST Investigators
        Hormone replacement therapy is associated with improved survival in women with advanced heart failure.
        J. Am. Coll. Cardiol. 2003 Oct 1; 42: 1238-1245
        • Nussmeier N.A.
        • Marino M.R.
        • Vaughn W.K.
        Hormone replacement therapy is associated with improved survival in women undergoing coronary artery bypass grafting.
        J. Thorac. Cardiovasc. Surg. 2002 Dec; 124: 1225-1229
        • White W.B.
        • Pitt B.
        • Preston R.A.
        • Hanes V.
        Antihypertensive effects of drospirenone with 17beta-estradiol, a novel hormone treatment in postmenopausal women with stage 1 hypertension.
        Circulation. 2005 Sep 27; 112: 1979-1984https://doi.org/10.1161/CIRCULATIONAHA.104.501502
        • White W.B.
        • Hanes V.
        • Chauhan V.
        • Pitt B.
        Effects of a new hormone therapy, drospirenone and 17-beta-estradiol, in postmenopausal women with hypertension.
        Hypertension. 2006 Aug; 48: 246-253https://doi.org/10.1161/01.HYP.0000232179.60442.84
        • Preston R.A.
        • Alonso A.
        • Panzitta D.
        • Zhang P.
        • Karara A.H.
        Additive effect of drospirenone/17-beta-estradiol in hypertensive postmenopausal women receiving enalapril.
        Am. J. Hypertens. 2002 Sep; 15: 816-822https://doi.org/10.1016/s0895-7061(02)02980-1
        • Preston R.A.
        • White W.B.
        • Pitt B.
        • Bakris G.
        • Norris P.M.
        • Hanes V.
        Effects of drospirenone/17-beta estradiol on BP and potassium balance in hypertensive postmenopausal women.
        Am. J. Hypertens. 2005 Jun; 18: 797-804https://doi.org/10.1016/j.amjhyper.2004.12.003
        • Preston R.A.
        • Norris P.M.
        • Alonso A.B.
        • Ni P.
        • Hanes V.
        • Karara A.H.
        Randomized, placebo-controlled trial of the effects of drospirenone-estradiol on BP and potassium balance in hypertensive postmenopausal women receiving hydrochlorothiazide.
        Menopause. 2007 May-Jun; 14: 408-414https://doi.org/10.1097/01.gme.0000243572.63322.f7
        • Kaya C.
        • Cengiz S.D.
        • Cengiz B.
        • Akgun G.
        Long-term effects of low-dose 17beta-estradiol plus dydrogesterone on 24-h ambulatory BP in healthy postmenopausal women: a 1-year, randomized, prospective study.
        Gynecol. Endocrinol. 2007 Oct; 23: 62-67https://doi.org/10.1080/09513590701584956
        • Sumino H.
        • Ichikawa S.
        • Kumakura H.
        • Takayama Y.
        • Kanda T.
        • Sakamaki T.
        • Kurabayashi M.
        Effects of hormone replacement therapy on office and ambulatory BP in Japanese hypertensive postmenopausal women.
        Hypertens. Res. 2003 May; 26: 369-376https://doi.org/10.1291/hypres.26.369
        • Modena M.G.
        • Molinari R.
        • Muia Jr., N.
        • Castelli A.
        • Pala F.
        • Rossi R.
        Double-blind randomized placebo-controlled study of transdermal estrogen replacement therapy on hypertensive postmenopausal women.
        Am. J. Hypertens. 1999 Oct; 12: 1000-1008https://doi.org/10.1016/s0895-7061(99)00074-6
        • Kawecka-Jaszcz K.
        • Czarnecka D.
        • Olszanecka A.
        • Rajzer M.
        • Jankowski P.
        The effect of hormone replacement therapy on arterial BP and vascular compliance in postmenopausal women with arterial hypertension.
        J. Hum. Hypertens. 2002 Jul; 16: 509-516https://doi.org/10.1038/sj.jhh.1001431
        • de Carvalho M.N.
        • Nobre F.
        • Mendes M.C.
        • Dos Reis R.M.
        • Ferriani R.A.
        • Silva de Sá M.F.
        Low-dose transdermal hormone therapy does not interfere with the BP of hypertensive menopausal women: a pilot study.
        Blood Press Monit. 2008 Oct; 13: 277-283https://doi.org/10.1097/MBP.0b013e32830d4b60
        • Lloyd G.
        • McGing E.
        • Cooper A.
        • Patel N.
        • Lumb P.J.
        • Wierzbicki A.S.
        • Jackson G.
        A randomised placebo controlled trial of the effects of tibolone on BP and lipids in hypertensive women.
        J. Hum. Hypertens. 2000 Feb; 14: 99-104https://doi.org/10.1038/sj.jhh.1000938
        • Andersson B.
        • Mattsson L.A.
        • Hahn L.
        • Mårin P.
        • Lapidus L.
        • Holm G.
        • Bengtsson B.A.
        • Björntorp P.
        Estrogen replacement therapy decreases hyperandrogenicity and improves glucose homeostasis and plasma lipids in postmenopausal women with noninsulin-dependent diabetes mellitus.
        J. Clin. Endocrinol. Metab. 1997 Feb; 82: 638-643
        • Araujo D.A.
        • Farias M.L.
        • Andrade A.T.
        Effects of transdermal and oral estrogen replacement on lipids and glucose metabolism in postmenopausal women with type 2 diabetes mellitus.
        Climacteric. 2002; 5: 286-292
        • Brussaard H.E.
        • Gevers Leuven J.A.
        • Frölich M.
        • Kluft C.
        • Krans H.M.
        Short-term oestrogen replacement therapy improves insulin resistance, lipids and fibrinolysis in postmenopausal women with NIDDM.
        Diabetologia. 1997; 40: 843-849https://doi.org/10.1007/s001250050758
        • Cornu C.
        • Mercier C.
        • Ffrench P.
        • et al.
        Postmenopause hormone treatment in women with NIDDM or impaired glucose tolerance: the MEDIA randomized clinical trial.
        Maturitas. 2000; 37: 95-104https://doi.org/10.1016/s0378-5122(00)00164-x
        • Darko D.A.
        • Dornhorst A.
        • Kennedy G.
        • Mandeno R.C.
        • Seed M.
        Glycaemic control and plasma lipoproteins in menopausal women with Type 2 diabetes treated with oral and transdermal combined hormone replacement therapy.
        Diabetes Res. Clin. Pract. 2000; 54 (Xllth International Symposium on Atherosclerosis, Stockholm, Sweden, June 25-29, 2000): 157-164
        • Friday K.E.
        • Dong C.
        • Fontenot R.U.
        Conjugated equine estrogen improves glycemic control and blood lipoproteins in postmenopausal women with type 2 diabetes.
        J. Clin. Endocrinol. Metab. 2001; 86: 48-52https://doi.org/10.1210/jcem.86.1.7094
        • Howard B.V.
        Postmenopausal hormone therapy is associated with atherosclerosis progression in women with abnormal glucose tolerance.
        Circulation. 2004 Jul 13; 110: 201-206
        • Kanaya A.M.
        • Herrington D.
        • Vittinghoff E.
        • Lin F.
        • Grady D.
        • Bittner V.
        • et al.
        Glycemic effects of postmenopausal hormone therapy: the Heart and Estrogen/progestin Replacement Study. A randomized, double-blind, placebo-controlled trial.
        Ann. Intern. Med. 2003; 138: 1e9
        • Kernohan A.F.
        • Sattar N.
        • Hilditch T.
        • Cleland S.J.
        • Small M.
        • Lumsden M.A.
        • et al.
        Effects of low-dose continuous combined hormone replacement therapy on glucose homeostasis and markers of cardiovascular risk in women with type 2 diabetes.
        Clin. Endocrinol. 2007; 66: 27e34
        • Lamon-Fava S.
        • Herrington D.M.
        • Horvath K.V.
        • Schaefer E.J.
        • Asztalos B.F.
        Effect of hormone replacement therapy on plasma lipoprotein levels and coronary atherosclerosis progression in postmenopausal women according to type 2 diabetes mellitus status.
        Metabolism. 2010; 59: 1794e800
        • Manning P.J.
        • Allum A.
        • Jones S.
        • Sutherland W.H.
        • Williams S.M.
        The effect of hormone replacement therapy on cardiovascular risk factors in type 2 diabetes: a randomized controlled trial.
        Arch. Intern. Med. 2001; 161: 1772-1776https://doi.org/10.1001/archinte.161.14.1772
        • McKenzie J.
        • Jaap A.J.
        • Gallacher S.
        • Kelly A.
        • Crawford L.
        • Greer I.A.
        • et al.
        Metabolic, inflammatory and haemostatic effects of a low-dose continuous combined HRT in women with type 2 diabetes: potentially safer with respect to vascular risk?.
        Clin. Endocrinol. 2003; 59: 682e9
        • Mosnier-Pudar H.
        • Faguer B.
        • Guyenne T.T.
        • Tchobroutsky G.
        Effets de la substitution par 17 beta estradiol percutané et progestérone orale sur la pression artérielle et les paramètres métaboliques chez des patientes ménopausées diabétiques non insulinodépendantes [Effects of deprivation and replacement by percutaneous 17 beta estradiol and oral progesterone on blood pressure and metabolic parameters in menopause patients with non-insulin-dependent diabetes].
        Arch. Mal. Coeur Vaiss. 1991; 84: 1111-1115
        • Perera M.
        • Sattar N.
        • Petrie J.R.
        • et al.
        The effects of transdermal estradiol in combination with oral norethisterone on lipoproteins, coagulation, and endothelial markers in postmenopausal women with type 2 diabetes: a randomized, placebo-controlled study.
        J. Clin. Endocrinol. Metab. 2001; 86: 1140-1143https://doi.org/10.1210/jcem.86.3.7297
        • Samaras K.
        • Hayward C.S.
        • Sullivan D.
        • Kelly R.P.
        • Campbell L.V.
        Effects of postmenopausal hormone replacement therapy on central abdominal fat, glycemic control, lipid metabolism, and vascular factors in type 2 diabetes: a prospective study.
        Diabetes Care. 1999; 22: 1401-1407https://doi.org/10.2337/diacare.22.9.1401
        • Sánchez-Rodríguez M.A.
        • Zacarías-Flores M.
        • Castrejón-Delgado L.
        • Ruiz-Rodríguez A.K.
        • Mendoza-Núñez V.M.
        Effects of hormone therapy on oxidative stress in postmenopausal women with metabolic syndrome.
        Int. J. Mol. Sci. 2016 Aug 24; 17 (PMID: 27563883; PMCID: PMC5037668): 1388https://doi.org/10.3390/ijms17091388
        • Scott A.R.
        • Dhindsa P.
        • Forsyth J.
        • Mansell P.
        Effect of hormone replacement therapy on cardiovascular risk factors in postmenopausal women with diabetes.
        Diabetes. Obes. Metab. 2004; 6: 16-22
        • Sumino H.
        Hormone replacement therapy decreases insulin resistance and lipid metabolism in Japanese postmenopausal women with impaired and normal glucose tolerance.
        Horm. Res. 2003; 60: 134-142
        • Sutherland W.H.
        • Manning P.J.
        • de Jong S.A.
        • Allum A.R.
        • Jones S.D.
        • Williams S.M.
        Hormone-replacement therapy increases sèrum paraoxonase arylesterase activity in diabetic postmenopausal women.
        Metabolism. 2001; 50: 319e24
        • Thunell L.
        • Andersson B.
        • Glassell M.
        • Mattsson L.A.
        The effect of continuous combined HRT on glucose homeostasis and plasma lipids. A placebo-controlled study in postmenopausal women with type 2 diabetes.
        Maturitas. 2006; 53: 430e8
        • Xue W.
        • Deng Y.
        • Wang Y.F.
        • Sun A.J.
        Effect of half-dose and standard-dose conjugated equine estrogens combined with natural progesterone or dydrogesterone on components of metabolic syndrome in healthy postmenopausal women: a Randomized Controlled Trial.
        Chin. Med. J. 2016 Dec 5; 129 (PMID: 27900987; PMCID: PMC5146781): 2773-2779https://doi.org/10.4103/0366-6999.194646
        • Manwaring P.
        • Morfis L.
        • Diamond T.
        • Howes L.G.
        The effects of hormone replacement therapy on plasma lipids in type II diabetes.
        Maturitas. 2000 Mar 31; 34: 239-247https://doi.org/10.1016/s0378- 5122(99)00112-7
        • Ferrara A.
        • Karter A.J.
        • Ackerson L.M.
        • Liu J.Y.
        • Selby J.V.
        • Northern California Kaiser Permanente Diabetes Registry
        Hormone replacement therapy is associated with better glycemic control in women with type 2 diabetes: the Northern California Kaiser Permanente Diabetes Registry.
        Diabetes Care. 2001; 24: 1144-1150
        • Ferrara A.
        Current use of unopposed estrogen and estrogen plus progestin and the risk of acute myocardial infarction among women with diabetes: the Northern California Kaiser Permanent Diabetes Registry, 1995-8.
        Circulation. 2003 Jan 7; 107: 43-48
        • Kim J.E.
        • Choi J.
        • Park J.
        • Lee J.K.
        • Shin A.
        • Park S.M.
        • Kang D.
        • Choi J.Y.
        Associations of postmenopausal hormone therapy with metabolic syndrome among diabetic and non-diabetic women.
        Maturitas. 2019 Mar; 121 (Epub 2018 Dec 20): 76-82https://doi.org/10.1016/j.maturitas.2018.12.012
        • Newton K.M.
        • LaCroix A.Z.
        • Heckbert S.R.
        • Abraham L.
        • McCulloch D.
        • Barlow W.
        Estrogen therapy and risk of cardiovascular events among women with type 2 diabetes.
        Diabetes Care. 2003; 26: 2810-2816https://doi.org/10.2337/diacare.26.10.2810
        • Gami A.S.
        • Wright R.S.
        • Ballman K.V.
        • Kopecky S.L.
        • Hayes S.N.
        Hormone replacement therapy and risk of acute myocardial infarction in postmenopausal women with diabetes mellitus.
        Am. J. Cardiol. 2003; 91: 1275-1277https://doi.org/10.1016/s0002-9149(03)00284-4
        • Crespo C.J.
        • Smit E.
        • Snelling A.
        • Sempos C.T.
        • Andersen R.E.
        • NHANES III
        Hormone replacement therapy and its relationship to lipid and glucose metabolism in diabetic and nondiabetic postmenopausal women: results from the Third National Health and Nutrition Examination Survey (NHANES III).
        Diabetes Care. 2002 Oct; 25: 1675-1680https://doi.org/10.2337/diacare.25.10.1675
        • Sites C.K.
        • Brochu M.
        • Tchernof A.
        • Poehlman E.T.
        Relationship between hormone replacement therapy use with body fat distribution and insulin sensitivity in obese postmenopausal women.
        Metabolism. 2001; 50: 835-840
        • Osmanağaoğlu M.A.
        • Osmanağaoğlu S.
        • Osmanağaoğlu T.
        • Okumuş B.
        • Bozkaya H.
        Effect of different preparations of hormone therapy on lipid and glucose metabolism, coagulation factors, and bone mineral density in overweight and obese postmenopausal women.
        Fertil. Steril. 2005; 84: 384-393
        • Canonico M.
        • Oger E.
        • Conard J.
        • Meyer G.
        • Lévesque H.
        • Trillot N.
        • Barrellier M.T.
        • Wahl D.
        • Emmerich J.
        • Scarabin P.Y.
        • EStrogen and THromboEmbolism Risk (ESTHER) Study Group
        Obesity and risk of venous thromboembolism among postmenopausal women: differential impact of hormone therapy by route of estrogen administration. The ESTHER Study.
        J. Thromb. Haemost. 2006 Jun; 4: 1259-1265https://doi.org/10.1111/j.1538-7836.2006.01933.x
        • Kane S.V.
        Hormonal replacement therapy after menopause is protective of disease activity in women with inflammatory bowel disease.
        Am. J. Gastroenterol. 2008 May; 103: 1193-1196
        • Di Martino V.
        Progression of liver fibrosis in women infected with hepatitis C: long-term benefit of estrogen exposure.
        Hepatology. 2004 Dec; 40: 1426-1433
        • Codes L.
        • Asselah T.
        • Cazals-Hatem D.
        • Tubach F.
        • Vidaud D.
        • Paraná R.
        • Bedossa P.
        • Valla D.
        • Marcellin P.
        Liver fibrosis in women with chronic hepatitis C: evidence for the negative role of the menopause and steatosis and the potential benefit of hormone replacement therapy.
        Gut. 2007 Mar; 56: 390-395https://doi.org/10.1136/gut.2006.101931
        • Rinaldi M.
        • Cagnacci A.
        • Pansini F.E.
        • de Aloysio D.
        • Sgarabotto M.P.
        • Bacchi-Modena A.
        Neutral effect of prolonged transdermal hormone therapy on liver function of postmenopausal women with chronic active hepatitis.
        Menopause. 2005 Sep-Oct; 12: 619-622
        • von Schoultz E.
        • Rutqvist L.E.
        • Stockholm Breast Cancer Study Group
        Menopausal hormone therapy after breast cancer: the Stockholm randomized trial.
        J. Natl. Cancer Inst. 2005 Apr 6; 97: 533-535
        • Fahlén M.
        • Fornander T.
        • Johansson H.
        • Johansson U.
        • Rutqvist L.E.
        • Wilking N.
        • von Schoultz E.
        Hormone replacement therapy after breast cancer: 10 year follow up of the Stockholm randomised trial.
        Eur. J. Cancer. 2013 Jan; 49: 52-59https://doi.org/10.1016/j.ejca.2012.07.003
        • Holmberg L.
        • Anderson H.
        • HABITS steering and data monitoring committees
        HABITS (hormonal replacement therapy after breast cancer–is it safe?), a randomised comparison: trial stopped.
        Lancet. 2004 Feb 7; 363: 453-455
        • Holmberg L.
        • Iversen O.E.
        • Rudenstam C.M.
        • Hammar M.
        • Kumpulainen E.
        • Jaskiewicz J.
        • Jassem J.
        • Dobaczewska D.
        • Fjosne H.E.
        • Peralta O.
        • Arriagada R.
        • Holmqvist M.
        • Maenpaa J.
        • HABITS Study Group
        Increased risk of recurrence after hormone replacement therapy in breast cancer survivors.
        J. Natl. Cancer Inst. 2008 Apr 2; 100: 475-482https://doi.org/10.1093/jnci/djn058
        • Marttunen M.B.
        • Hietanen P.
        • Pyrhönen S.
        • Tiitinen A.
        • Ylikorkala O.
        A prospective study on women with a history of breast cancer and with or without estrogen replacement therapy.
        Maturitas. 2001 Sep 28; 39: 217-225
        • Decker D.A.
        • Pettinga J.E.
        • VanderVelde N.
        • Huang R.R.
        • Kestin L.
        • Burdakin J.H.
        Estrogen replacement therapy in breast cancer survivors: a matched-controlled series.
        Menopause. 2003 Jul-Aug; 10: 277-285
        • Vassilopoulou-Sellin R.
        • Cohen D.S.
        • Hortobagyi G.N.
        • Klein M.J.
        • McNeese M.
        • Singletary S.E.
        • Smith T.L.
        • Theriault R.L.
        Estrogen replacement therapy for menopausal women with a history of breast carcinoma: results of a 5-year, prospective study.
        Cancer. 2002 Nov 1; 95: 1817-1826
        • Durna E.M.
        • Wren B.G.
        • Heller G.Z.
        • Leader L.R.
        • Sjoblom P.
        • Eden J.A.
        Hormone replacement therapy after a diagnosis of breast cancer: cancer recurrence and mortality.
        Med. J. Aust. 2002 Oct 7; 177: 347-351
        • Beckmann M.W.
        • Jap D.
        • Djahansouzi S.
        • Nestle-Krämling C.
        • Kuschel B.
        • Dall P.
        • Brumm C.
        • Bender H.G.
        Hormone replacement therapy after treatment of breast cancer: effects on postmenopausal symptoms, bone mineral density and recurrence rates.
        Oncology. 2001; 60: 199-206
        • O’Meara E.S.
        • Rossing M.A.
        • Daling J.R.
        • Elmore J.G.
        • Barlow W.E.
        • Weiss N.S.
        Hormone replacement therapy after a diagnosis of breast cancer in relation to recurrence and mortality.
        J. Natl. Cancer Inst. 2001 May 16; 93: 754-762
        • Kenemans P.
        • Bundred N.J.
        • Foidart J.M.
        • Kubista E.
        • von Schoultz B.
        • Sismondi P.
        • Vassilopoulou-Sellin R.
        • Yip C.H.
        • Egberts J.
        • Mol-Arts M.
        • Mulder R.
        • van Os S.
        • Beckmann M.W.
        • LIBERATE Study Group
        Safety and efficacy of tibolone in breast-cancer patients with vasomotor symptoms: a double-blind, randomised, non-inferiority trial.
        Lancet Oncol. 2009 Feb; 10: 135-146https://doi.org/10.1016/S1470- 2045(08)70341-3
        • DiSaia P.J.
        • Brewster W.R.
        • Ziogas A.
        • Anton-Culver H.
        Breast cancer survival and hormone replacement therapy: a cohort analysis.
        Am. J. Clin. Oncol. 2000 Dec; 23: 541-545
        • DiSaia P.J.
        • Grosen E.A.
        • Kurosaki T.
        • Gildea M.
        • Cowan B.
        • Anton-Culver H.
        Hormone replacement therapy in breast cancer survivors: a cohort study.
        Am. J. Obstet. Gynecol. 1996 May; 174: 1494-1498
        • Cai B.
        • Simon J.
        • Villa P.
        • Biglia N.
        • Panay N.
        • Djumaeva S.
        • Particco M.
        • Kanakamedala H.
        • Altomare C.
        No increase in incidence or risk of recurrence of breast cancer in ospemifene-treated patients with vulvovaginal atrophy (VVA).
        Maturitas. 2020 Dec; 142: 38-44
        • Eisen A.
        • Lubinski J.
        • Gronwald J.
        • Moller P.
        • Lynch H.T.
        • Klijn J.
        • Kim-Sing C.
        • Neuhausen S.L.
        • Gilbert L.
        • Ghadirian P.
        • Manoukian S.
        • Rennert G.
        • Friedman E.
        • Isaacs C.
        • Rosen E.
        • Rosen B.
        • Daly M.
        • Sun P.
        • Narod S.A.
        • Hereditary Breast Cancer Clinical Study Group
        Hormone therapy and the risk of breast cancer in BRCA1 mutation carriers.
        J. Natl. Cancer Inst. 2008 Oct 1; 100: 1361-1367https://doi.org/10.1093/jnci/djn313
        • Kotsopoulos J.
        • Huzarski T.
        • Gronwald J.
        • Moller P.
        • Lynch H.T.
        • Neuhausen S.L.
        • Senter L.
        • Demsky R.
        • Foulkes W.D.
        • Eng C.
        • Karlan B.
        • Tung N.
        • Singer C.F.
        • Sun P.
        • Lubinski J.
        • Narod S.A.
        Hormone replacement therapy after menopause and risk of breast cancer in BRCA1 mutation carriers: a case-control study.
        Breast Cancer Res. Treat. 2016 Jan; 155 (Epub 2016 Jan 16): 365-373https://doi.org/10.1007/s10549-016-3685-3
        • Rebbeck T.R.
        • Friebel T.
        • Wagner T.
        • Lynch H.T.
        • Garber J.E.
        • Daly M.B.
        • Isaacs C.
        • Olopade O.I.
        • Neuhausen S.L.
        • van’t Veer L.
        • Eeles R.
        • Evans D.G.
        • Tomlinson G.
        • Matloff E.
        • Narod S.A.
        • Eisen A.
        • Domchek S.
        • Armstrong K.
        • Weber B.L.
        • PROSE Study Group
        Effect of short-term hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group.
        J. Clin. Oncol. 2005 Nov 1; 23 (Epub 2005 Oct 11. PMID: 16219936): 7804-7810https://doi.org/10.1200/JCO.2004.00.8151
        • Kotsopoulos J.
        • Gronwald J.
        • Karlan B.Y.
        • Huzarski T.
        • Tung N.
        • Moller P.
        • Armel S.
        • Lynch H.T.
        • Senter L.
        • Eisen A.
        • Singer C.F.
        • Foulkes W.D.
        • Jacobson M.R.
        • Sun P.
        • Lubinski J.
        • Narod S.A.
        • Hereditary Breast Cancer Clinical Study Group
        Hormone replacement therapy after oophorectomy and breast cancer risk among BRCA1 mutation carriers.
        JAMA Oncol. 2018 Aug 1; 4: 1059-1065https://doi.org/10.1001/jamaoncol.2018.0211
        • Eeles R.A.
        • Morden J.P.
        • Gore M.
        • Mansi J.
        • Glees J.
        • Wenxzl M.
        • et al.
        Adjuvant hormone therapy may improve survival in epithelial ovarian cancer: results of the AHT Randomized Trial.
        J. Clin. Oncol. 2015; 33: 4138-4144https://doi.org/10.1200/JCO.2015.60.9719
        • Li L.
        • Pan Z.
        • Gao K.
        • Zhang W.
        • Luo Y.
        • Yao Z.
        • et al.
        Impact of postoperative hormone replacement therapy on life quality and prognosis in patients with ovarian malignancy.
        Oncol. Lett. 2012; 3: 244-249
        • Guidozzi F.
        • Daponte A.
        Estrogen replacement therapy for ovarian carcinoma survivors: a randomized controlled trial.
        Cancer. 1999; 86: 1013-1018
        • Eeles R.A.
        • Tan S.
        • Wiltshaw E.
        • et al.
        Hormone replacement therapy and survival after surgery for ovarian cancer.
        BMJ. 1991; 302: 259-262
        • Ursic-Vrscaj M.
        • Bebar S.
        • Zakelj M.P.
        Hormone replacement therapy after invasive ovarian serous cystadenocarcinoma treatment: the effect on survival.
        Menopause. 2001; 8: 70-75
        • Mascarenhas C.
        • Lambe M.
        • Bellocco R.
        • et al.
        Use of hormone replacement therapy before and after ovarian cancer diagnosis and ovarian cancer survival.
        Int. J. Cancer. 2006; 119: 2907-2915
        • Wen Y.
        • Huang H.
        • Huang H.
        • Wu M.
        • Shen K.
        • Pan L.
        The safety of postoperative hormone replacement therapy in epithelial ovarian cancer patients in China.
        Climacteric. 2013; 16: 673-681
        • Power L.
        • Lefas G.
        • Lambert P.
        • Kim D.
        • Evaniuk D.
        • Lotocki R.
        • Dean E.
        • Nachtigal M.W.
        • Altman A.D.
        Hormone use after nonserous epithelial ovarian cancer: overall and disease-free survival.
        Obstet. Gynecol. 2016 May; 127: 837-847
        • Zhang Y.L.
        • Chen J.H.
        • Lu W.
        • Li B.L.
        • Zhu Q.Y.
        • Wan X.P.
        Efficacy of postoperative hormone replacement therapy on prognosis of patients with serous ovarian carcinoma.
        Chin. Med. J. 2016 Jun 5; 129: 1316-1321
        • Barakat R.R.
        • Bundy B.N.
        • Spirtos N.M.
        • Bell J.
        • Mannel R.S.
        • Gynecologic Oncology Group Study
        Randomized double-blind trial of estrogen replacement therapy versus placebo in stage I or II endometrial cancer: a Gynecologic Oncology Group Study.
        J. Clin. Oncol. 2006; 24: 587-592
        • Ayhan A.
        • Taskiran C.
        • Simsek S.
        • Sever A.
        Does immediate hormone replacement therapy affect the oncologic outcome in endometrial cancer survivors?.
        Int. J. Gynecol. Cancer. 2006; 16: 805-808
        • Suriano K.A.
        • McHale M.
        • McLaren C.E.
        • Li K.T.
        • Re A.
        • DiSaia P.J.
        Estrogen replacement therapy in endometrial cancer patients: a matched control study.
        Obstet. Gynecol. 2001; 97: 555-560
        • Arteaga-Gómez A.C.
        • Castellanos-Barroso G.
        • Colin-Valenzuela A.
        • García-Vargas J.
        • Márquez-Acosta G.
        • Reyes-Muñoz E.
        Hormone therapy effect in postmenopausal women with history of endometrial cancer.
        Ginecol. Obstet. Mex. 2011 Jan; 79: 11-17
        • Creasman W.T.
        • Henderson D.
        • Hinshaw W.
        • Clarke-Pearson D.L.
        Estrogen replacement therapy in the patient treated for endometrial cancer.
        Obstet. Gynecol. 1986; 67: 326-330
        • Lee R.B.
        • Burke T.W.
        • Park R.C.
        Estrogen replacement therapy following treatment for stage I endometrial carcinoma.
        Gynecol. Oncol. 1990; 36: 189-191
        • Chapman J.A.
        • DiSaia P.J.
        • Osann K.
        • Roth P.D.
        • Gillotte D.L.
        • Berman M.L.
        Estrogen replacement in surgical stage I and II endometrial cancer survivors.
        Am. J. Obstet. Gynecol. 1996; 175: 1195-1200
        • Lim S.
        • Kim Y.H.
        • Lee K.B.
        • Lee J.M.
        The influence of hormone therapy with drospirenone-estradiol on endometrioid type endometrial cancer patients.
        J. Gynecol. Oncol. 2018 Sep; 29e72https://doi.org/10.3802/jgo.2018.29.e72
        • Cho H.W.
        • Ouh Y.T.
        • Lee J.K.
        • Hong J.H.
        Effects of hormone therapy on recurrence in endometrial cancer survivors: a nationwide study using the Korean Health Insurance Review and Assessment Service database.
        J. Gynecol. Oncol. 2019 Jul; 30e51https://doi.org/10.3802/jgo.2019.30.e51
        • Ploch E.
        Hormone replacement therapy in patients after cervical cancer treatment.
        Gynecol. Oncol. 1987; 26: 169-177
        • Chan J.A.
        • Meyerhardt J.A.
        • Chan A.T.
        • Giovannucci E.L.
        • Colditz G.A.
        • Fuchs C.S.
        Hormone replacement therapy and survival after colorectal cancer diagnosis.
        J. Clin. Oncol. 2006; 24: 5680-5686
        • Arem H.
        • Park Y.
        • Felix A.S.
        • Zervoudakis A.
        • Brinton L.A.
        • Matthews C.E.
        • Gunter M.J.
        Reproductive and hormonal factors and mortality among women with colorectal cancer in the NIH-AARP Diet and Health Study.
        Br. J. Cancer. 2015; 113: 562-568
        • Mandelson M.T.
        • Miglioretti D.
        • Newcomb P.A.
        • Harrison R.
        • Potter J.D.
        Hormone replacement therapy in relation to survival in women diagnosed with colon cancer.
        Cancer Causes Control. 2003; 14: 979-984
        • Ji J.
        • Sundquist J.
        • Sundquist K.
        Use of hormone replacement therapy improves the prognosis in patients with colorectal cancer: a population-based study in Sweden.
        Int. J. Cancer. 2018; 142: 2003-2010
        • Slattery M.L.
        • Anderson K.
        • Samowitz W.
        • Edwards S.L.
        • Curtin K.
        • Caan B.
        • Potter J.D.
        Hormone replacement therapy and improved survival among postmenopausal women diagnosed with colon cancer (USA).
        Cancer Causes Control. 1999; 10: 467-473
        • Ganti A.K.
        • Sahmoun A.E.
        • Panwalkar A.W.
        • et al.
        Hormone replacement therapy is associated with decreased survival in women with lung cancer[J].
        J. Clin. Oncol. 2006; 24: 59-63
        • Ayeni O.
        • Robinson A.
        Hormone replacement therapy and outcomes for women with non-small-cell lung cancer: can an association be confirmed?.
        Curr. Oncol. 2009; 16: 21-25
        • Katcoff H.
        • Wenzlaff A.S.
        • Schwartz A.G.
        Survival in women with NSCLC: the role of reproductive history and hormone use.
        J. Thorac. Oncol. 2014; 9: 355-361
        • Huang B.
        • Carloss H.
        • Wyatt S.W.
        • et al.
        Hormone replacement therapy and survival in lung cancer in postmenopausal women in a rural population.
        Cancer. 2009; 115: 4167-4175
        • Clague J.
        • Reynolds P.
        • Henderson K.D.
        • Sullivan-Halley J.
        • Ma H.
        • Lacey Jr., J.V.
        • Chang S.
        • Delclos G.L.
        • Du X.L.
        • Forman M.R.
        • Bernstein L.
        Menopausal hormone therapy and lung cancer-specific mortality following diagnosis: the California Teachers Study.
        PLoS One. 2014; 9e103735
        • Li K.
        • Chen L.
        • Huang Y.
        • Luan X.
        Meta-analysis for the effect of hormone replacement therapy on survival rate in female with lung cancer.
        Zhong Nan Da Xue Bao Yi Xue Ban. 2020; 45: 372-377
        • MacKie R.M.
        • Bray C.A.
        Hormone replacement therapy after surgery for stage 1 or 2 cutaneous melanoma.
        Br. J. Cancer. 2004; 90: 770-772
        • Malek A.M.
        • Vladutiu C.J.
        • Meyer M.L.
        • Cushman M.
        • Newman R.
        • Lisabeth L.D.
        • Kleindorfer D.
        • Lakkur S.
        • Howard V.J.
        The association of age at menopause and all-cause and cause-specific mortality by race, postmenopausal hormone use, and smoking status.
        Prev. Med. Rep. 2019; 15: 100955https://doi.org/10.1016/j.pmedr.2019.100955
        • Wilson P.W.
        • Garrison R.J.
        • Castelli W.P.
        Postmenopausal estrogen use, cigarette smoking, and cardiovascular morbidity in women over 50. The Framingham Study.
        N. Engl. J. Med. 1985; 313: 1038-1043https://doi.org/10.1056/NEJM198510243131702
        • Mann R.D.
        • Lis Y.
        • Chukwujindu J.
        • Chanter D.O.
        A study of the association between hormone replacement therapy, smoking and the occurrence of myocardial infarction in women.
        J. Clin. Epidemiol. 1994; 47: 307-312https://doi.org/10.1016/0895-4356(94)90014-0
        • Mueck A.O.
        • Seeger H.
        Smoking, estradiol metabolism and hormone replacement therapy.
        Arzneimittelforschung. 2003; 53: 1-11https://doi.org/10.1055/s-0031-1297063
        • Mueck A.O.
        • Seeger H.
        Smoking, estradiol metabolism and hormone replacement therapy.
        Curr. Med. Chem. Cardiovasc. Hematol. Agents. 2005 Jan; 3: 45-54https://doi.org/10.2174/1568016052773270
        • Driul L.
        • Stella A.
        • Marchesoni D.
        Twenty-four hour ambulatory blood pressure in postmenopausal smokers and non-smokers on hormone therapy.
        Int. J. Gynecol. Obstet. 2005; 90: 82-83
        • Geisler J.
        • Omsjø I.H.
        • Helle S.I.
        • Ekse D.
        • Silsand T.
        • Lønning P.E.
        Plasma oestrogen fractions in postmenopausal women receiving hormone replacement therapy: influence of route of administration and cigarette smoking.
        J. Endocrinol. 1999; 162: 265-270https://doi.org/10.1677/joe.0.1620265
        • Abernethy D.R.
        • Todd E.L.
        Impairment of caffeine clearance by chronic use of low-dose oestrogen-containing oral contraceptives.
        Eur. J. Clin. Pharmacol. 1985; 28: 425-428
        • Abernethy D.R.
        • Greenblatt D.J.
        • Shader R.I.
        Imipramine disposition in users of oral contraceptive steroids.
        Clin. Pharmacol. Ther. 1984 Jun; 35: 792-797
        • Abernethy D.R.
        • Greenblatt D.J.
        • Divoll M.
        • Arendt R.
        • Ochs H.R.
        • Shader R.I.
        Impairment of diazepam metabolism by low-dose estrogen-containing oral-contraceptive steroids.
        N. Engl. J. Med. 1982 Apr 1; 306: 791-792
        • Altschuler S.L.
        • Valenteen J.W.
        Amenorrhea following rifampin administration during oral contraceptive use.
        Obstet. Gynecol. 1974 Nov; 44: 771-772
        • Andrews E.
        • Damle B.D.
        • Fang A.
        • Foster G.
        • Crownover P.
        • LaBadie R.
        • Glue P.
        Pharmacokinetics and tolerability of voriconazole and a combination oral contraceptive co-administered in healthy female subjects.
        Br. J. Clin. Pharmacol. 2008; 65: 531-539
        • Back D.J.
        • Breckenridge A.M.
        • Crawford F.
        • MacIver M.
        • Orme M.L.
        • Park B.K.
        • Rowe P.H.
        • Smith E.
        The effect of rifampicin on norethisterone pharmacokinetics.
        Eur. J. Clin. Pharmacol. 1979 Apr 17; 15: 193-197
        • Back D.J.
        • Breckenridge A.M.
        • Crawford F.E.
        • Hall J.M.
        • MacIver M.
        • Orme M.L.
        • Rowe P.H.
        • Smith E.
        • Watts M.J.
        The effect of rifampicin on the pharmacokinetics of ethynylestradiol in women.
        Contraception. 1980 Feb; 21: 135-143
        • Baisini O.
        • Benini F.
        • Petraglia F.
        • Kuhnz W.
        • Scalia S.
        • Marschall H.U.
        • Brunetti G.
        • Tauschel H.D.
        • Lanzini A.
        Ursodeoxycholic acid does not affect ethinylestradiol bioavailability in women taking oral contraceptives.
        Eur. J. Clin. Pharmacol. 2004 Sep; 60: 481-487
        • Barditch-Crovo P.
        • Trapnell C.B.
        • Ette E.
        • Zacur H.A.
        • Coresh J.
        • Rocco L.E.
        • Hendrix C.W.
        • Flexner C.
        The effects of rifampin and rifabutin on the pharmacokinetics and pharmacodynamics of a combination oral contraceptive.
        Clin. Pharmacol. Ther. 1999 Apr; 65: 428-438
        • Bessot J.C.
        • Petitjean R.
        • Vandevenne A.
        • Rempp M.
        • Burghard G.
        Rifampicin interference with oral contraceptives.
        J. Med. Strasb. 1977 Mar; 8: 131-133
        • Blode H.
        • Zeun S.
        • Parke S.
        • Zimmermann T.
        • Rohde B.
        • Mellinger U.
        • Kunz M.
        Evaluation of the effects of rifampicin, ketoconazole and erythromycin on the steady-state pharmacokinetics of the components of a novel oral contraceptive containing estradiol valerate and dienogest in healthy postmenopausal women.
        Contraception. 2012; 86: 337-344
        • Bolt H.M.
        • Bolt M.
        • Kappus H.
        Interaction of rifampicin treatment with pharmacokinetics and metabolism of ethinyloestradiol in man.
        Acta Endocrinol. 1977 May; 85: 189-197
        • Bolt H.M.
        • Kappus H.
        • Bolt M.
        Effect of rifampicin treatment on the metabolism of oestradiol and 17alpha-ethinyloestradiol by human liver microsomes.
        Eur. J. Clin. Pharmacol. 1975 Jun 13; 8: 301-307
        • Breckenridge A.M.
        • Back D.J.
        • Orme M.
        Interactions between oral contraceptives and other drugs.
        Pharmacol. Ther. 1979; 7: 617-626
        • Christen R.D.
        • McClay E.F.
        • Plaxe S.C.
        • Yen S.S.
        • Kim S.
        • Kirmani S.
        • Wilgus L.L.
        • Heath D.D.
        • Shalinsky D.R.
        • Freddo J.L.
        • et al.
        Phase I/pharmacokinetic study of high-dose progesterone and doxorubicin.
        J. Clin. Oncol. 1993 Dec; 11: 2417-2426
        • Cotton F.
        • Sorlin P.
        • Corvilain B.
        • Fockedey J.M.
        • Capel P.
        Interference with oral anticoagulant treatment by oestrogen–influence of oestrogen administration route.
        Thromb. Haemost. 1999 Mar; 81: 471-472
        • Coulam C.B.
        • Annegers J.F.
        Do anticonvulsants reduce the efficacy of oral contraceptives?.
        Epilepsia. 1979 Oct; 20: 519-525
        • Crawford P.
        • Chadwick D.
        • Cleland P.
        • Tjia J.
        • Cowie A.
        • Back D.J.
        • Orme M.L.
        The lack of effect of sodium valproate on the pharmacokinetics of oral contraceptive steroids.
        Contraception. 1986 Jan; 33: 23-29
        • de Teresa E.
        • Vera A.
        • Ortigosa J.
        • Pulpon L.A.
        • Arus A.P.
        • de Artaza M.
        Interaction between anticoagulants and contraceptives: an unsuspected finding.
        Br. Med. J. 1979 Nov 17; 2: 1260-1261
        • Decensi A.
        • Gandini S.
        • Serrano D.
        • Cazzaniga M.
        • Pizzamiglio M.
        • Maffini F.
        • Pelosi G.
        • Daldoss C.
        • Omodei U.
        • Johansson H.
        • Macis D.
        • Lazzeroni M.
        • Penotti M.
        • Sironi L.
        • Moroni S.
        • Bianco V.
        • Rondanina G.
        • Gjerde J.
        • Guerrieri-Gonzaga A.
        • Bonanni B.
        Randomized dose-ranging trial of tamoxifen at low doses in hormone replacement therapy users.
        J. Clin. Oncol. 2007 Sep 20; 25: 4201-4209
        • Dew J.E.
        • Wren B.G.
        • Eden J.A.
        Tamoxifen, hormone receptors and hormone replacement therapy in women previously treated for breast cancer: a cohort study.
        Climacteric. 2002 Jun; 5: 151-155
        • Diamond M.P.
        • Greene J.W.
        • Thompson J.M.
        • VanHooydonk J.E.
        • Wentz A.C.
        Interaction of anticonvulsants and oral contraceptives in epileptic adolescents.
        Contraception. 1985 Jun; 31: 623-632
        • Elbers J.
        • Hageluken C.
        • Wadham A.
        Tibolone (Livial®) enhances warfarin-induced anticoagulation in postmenopausal women.
        Maturitas. 2007 Jan 20; 56: 94-100
        • Ellinwood Jr., E.H.
        • Easler M.E.
        • Linnoila M.
        • Molter D.W.
        • Heatherly D.G.
        • Bjornsson T.D.
        Effects of oral contraceptives on diazepam-induced psychomotor impairment.
        Clin. Pharmacol. Ther. 1984 Mar; 35: 360-366
        • Ellison J.
        • Thomson A.J.
        • Greer I.A.
        • Walker I.D.
        Drug points: apparent interaction between warfarin and levonorgestrel used for emergency contraception.
        BMJ. 2000 Dec 2; 321: 1382
        • Espir M.
        • Walker M.E.
        • Lawson J.P.
        Epilepsy and oral contraception.
        Br. Med. J. 1969 Feb 1; 1: 294-295
        • Frey B.M.
        • Schaad H.J.
        • Frey F.J.
        Pharmacokinetic interaction of contraceptive steroids with prednisone and prednisolone.
        Eur. J. Clin. Pharmacol. 1984; 26: 505-511
        • Garwood C.L.
        • Van Schepen K.A.
        • McDonough R.P.
        • Sullivan A.L.
        Increased thyroid-stimulating hormone levels associated with concomitant administration of levothyroxine and raloxifene.
        Pharmacotherapy. 2006 Jun; 26: 881-885
        • Gringras M.
        • Beaumont G.
        • Grieve A.
        Clomipramine and oral contraceptives: an interaction study--clinical findings.
        J. Int. Med. Res. 1980; 8: 76-80
        • Grözinger M.
        • Härtter S.
        • Hiemke C.
        • Griese E.U.
        • Röschke J.
        Interaction of modafinil and clomipramine as comedication in a narcoleptic patient.
        Clin. Neuropharmacol. 1998 Mar-Apr; 21: 127-129
        • Gundersen S.
        • Hannisdal E.
        • Lundgren S.
        • Wist E.
        Weekly doxorubicin with or without high-dose medroxyprogesterone acetate in hormone-resistant advanced breast cancer. A randomised study. The Norwegian Breast Cancer Group.
        Eur. J. Cancer. 1994; 30A: 1775-1778
        • Gupta K.C.
        • Ali M.Y.
        Failure of oral contraceptive with rifampicin.
        Med. J. Zambia. 1980 Dec-1981 Jan; 15: 23
        • Härtter S.
        • Nordmark A.
        • Rose D.M.
        • Bertilsson L.
        • Tybring G.
        • Laine K.
        Effects of caffeine intake on the pharmacokinetics of melatonin, a probe drug for CYP1A2 activity.
        Br. J. Clin. Pharmacol. 2003 Dec; 56: 679-682
        • Health Canada
        Important New Safety Information Concerning the Antiepileptic, Lamotrigina, September 27.
        2004
        • Hempel E.
        • Klinger W.
        Drug stimulated biotransformation of hormonal steroid contraceptives: clinical implications.
        Drugs. 1976 Dec; 12: 442-448
        • Hilli J.
        • Korhonen T.
        • Turpeinen M.
        • Hokkanen J.
        • Mattila S.
        • Laine K.
        The effect of oral contraceptives on the pharmacokinetics of melatonin in healthy subjects with CYP1A2 g.-163C>A polymorphism.
        J. Clin. Pharmacol. 2008 Aug; 48: 986-994
        • Hirsch A.
        • Tillement J.P.
        • Chretien J.
        Effets contrariants de la rifampicine sur les contraceptifs oraux: a propos de trois grossesses non desiree chez trois malades.
        Revue française des maladies respiratoires. 1975; 2: 174-182
        • Jochemsen R.
        • van der Graaff M.
        • Boeijinga J.K.
        • Breimer D.D.
        Influence of sex, menstrual cycle and oral contraception on the disposition of nitrazepam.
        Br. J. Clin. Pharmacol. 1982 Mar; 13: 319-324
        • John V.A.
        • Luscombe D.K.
        • Kemp H.
        Effects of age, cigarette smoking and the oral contraceptive on the pharmacokinetics of clomipramine and its desmethyl metabolite during chronic dosing.
        J. Int. Med. Res. 1980; 8: 88-95
        • Joshi J.V.
        • Joshi U.M.
        • Sankolli G.M.
        • Gupta K.
        • Rao A.P.
        • Hazari K.
        • Sheth U.K.
        • Saxena B.N.
        A study of interaction of a low-dose combination oral contraceptive with anti-tubercular drugs.
        Contraception. 1980 Jun; 21: 617-629
        • Jusko W.J.
        • Gardner M.J.
        • Mangione A.
        • Schentag J.J.
        • Koup J.R.
        • Vance J.W.
        Factors affecting theophylline clearances: age, tobacco, marijuana, cirrhosis, congestive heart failure, obesity, oral contraceptives, benzodiazepines, barbiturates, and ethanol.
        J. Pharm. Sci. 1979 Nov; 68: 1358-1366
        • Kenyon I.E.
        Unplanned pregnancy in an epileptic.
        Br. Med. J. 1972 Mar 11; 1: 686-687
        • Khurana R.C.
        Estrogen-imipramine interaction.
        JAMA. 1972 Nov 6; 222: 702-703
        • Klosterskov Jensen P.
        • Saano V.
        • Haring P.
        • Svenstrup B.
        • Menge G.P.
        Possible interaction between oxcarbazepine and an oral contraceptive.
        Epilepsia. 1992 Nov-Dec; 33: 1149-1152
        • Kornstein S.G.
        • Toups M.
        • Rush A.J.
        • Wisniewski S.R.
        • Thase M.E.
        • Luther J.
        • Warden D.
        • Fava M.
        • Trivedi M.H.
        Do menopausal status and use of hormone therapy affect antidepressant treatment response? Findings from the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study.
        J. Women’s Health (Larchmt). 2013; 22: 121-131
        • Krishnan K.R.
        • France R.D.
        • Ellinwood Jr., E.H.
        Tricyclic-induced akathisia in patients taking conjugated estrogens.
        Am. J. Psychiatry. 1984 May; 141: 696-697
        • Kropp R.
        Rifampicin und Ovulationshemmer [Rifampicin and oral contraceptives (author’s transl)].
        Prax. Pneumol. 1974 May; 28: 270-272
        • Kovács I.
        • Somos P.
        • Hámori M.
        Examination of the potential interaction between ketoconazole (Nizoral) and oral contraceptives with special regard to products of low hormone content (Rigevidon, Anteovin).
        Ther. Hung. 1986; 34: 167-170
        • Krishnan K.R.
        • France R.D.
        • Ellinwood Jr., E.H.
        Tricyclic-induced akathisia in patients taking conjugated estrogens.
        Am. J. Psychiatry. 1984 May; 141: 696-697
        • Kroboth P.D.
        • Smith R.B.
        • Stoehr G.P.
        • Juhl R.P.
        Pharmacodynamic evaluation of the benzodiazepine-oral contraceptive interaction.
        Clin. Pharmacol. Ther. 1985 Nov; 38: 525-532
        • Kropp R.
        [Rifampicin and oral contraceptives (author’s transl)]. [German]. Praxis der Pneumologie vereinigt mit Der Tuberkulosearzt.
        28. 1974: 270-272
        • Kutt H.
        • McDowell F.
        Management of epilepsy with diphenylhydantoin sodium. Dosage regulation for problem patients.
        JAMA. 1968 Mar 11; 203: 969-972
        • Lafaix Ch.
        • Cadoz M.
        • Richard A.
        • Pafouillard P.
        L’effet antipilule de la rifampicine.
        Méd. Hyg. 1976; 1181: 181
        • Laine K.
        • Anttila M.
        • Helminen A.
        • Karnani H.
        • Huupponen R.
        Dose linearity study of selegiline pharmacokinetics after oral administration: evidence for strong drug interaction with female sex steroids.
        Br. J. Clin. Pharmacol. 1999 Mar; 47: 249-254
        • LeBel M.
        • Masson E.
        • Guilbert E.
        • et al.
        Effects of rifabutin and rifampicin on the pharmacokinetics of ethinylestradiol and norethindrone.
        J. Clin. Pharmacol. 1998; 38: 1042-1050
        • Luscombe D.K.
        • Wright J.
        • Jain V.K.
        Plasma level studies of clomipramine and desmethylclomipramine following intravenous infusions of clomipramine in depressive patients.
        Postgrad. Med. J. 1977; 53: 88-96
        • McLintock L.A.
        • Dykes A.
        • Tait R.C.
        • Walker I.D.
        Interaction between hormone replacement therapy preparations and oral anticoagulant therapy.
        Br. J. Obstet. Gynaecol. 2003 Aug; 11088: 777-779
        • Meyer F.P.
        • Canzler E.
        • Giers H.
        • Walther H.
        Zeitverlauf der hemmung der coffeinelimination unter dem einfluß des oralen depotkontrazeptivum Deposiston®.
        Zentralbl. Gynakol. 1991; 113: 297-302
        • Miners J.O.
        • Attwood J.
        • Birkett D.J.
        Influence of sex and oral contraceptive steroids on paracetamol metabolism.
        Br. J. Clin. Pharmacol. 1983 Nov; 16: 503-509
        • Mitchell M.C.
        • Hanew T.
        • Meredith C.G.
        • Schenker S.
        Effects of oral contraceptive steroids on acetaminophen metabolism and elimination.
        Clin. Pharmacol. Ther. 1983 Jul; 34: 48-53
        • Nelson D.H.
        • Tanney H.
        • Mestman G.
        • Gieschen V.W.
        • Wilson L.D.
        Potentiation of the biologic effect of administered cortisol by estrogen treatment.
        J. Clin. Endocrinol. Metab. 1963 Mar; 23: 261-265
        • Nocke-Finck L.
        • Breuer H.
        • Reimers D.
        Wirkung von Rifampicin auf den Menstruationszyklus und die Ostrogenausscheidung bei Einnahme oraler Kontrazeptiva [Effects of rifampicin on the menstrual cycle and on oestrogen excretion in patients taking oral contraceptives].
        Dtsch. Med. Wochenschr. 1973 Aug 11; 98: 1521-1523
        • Palovaara S.
        • Anttila M.
        • Nyman L.
        • Laine K.
        Effect of concomitant hormone replacement therapy containing estradiol and levonorgestrel on the pharmacokinetics of selegiline.
        Eur. J. Clin. Pharmacol. 2002 Jul; 58: 259-263
        • Patwardhan R.V.
        • Desmond P.V.
        • Johnson R.F.
        • Schenker S.
        Impaired elimination of caffeine by oral contraceptive steroids.
        J. Lab. Clin. Med. 1980; 95: 603-608
        • Pillans P.I.
        • Sparrow M.J.
        Pregnancy associated with a combined oral contraceptive and itraconazole.
        N. Z. Med. J. 1993; 106: 436
        • Pisoni C.N.
        • Cuadrado M.J.
        • Khamashta M.A.
        • Hunt B.J.
        Treatment of menorrhagia associated with oral anticoagulation: efficacy and safety of the levonorgestrel releasing intrauterine device (Mirena coil).
        Lupus. 2006; 15: 877-880
        • Pollock B.G.
        • Wylie M.
        • Stack J.A.
        • Sorisio D.A.
        • Thompson D.S.
        • Kirshner M.A.
        • Folan M.M.
        • Condifer K.A.
        Inhibition of caffeine metabolism by estrogen replacement therapy in postmenopausal women.
        J. Clin. Pharmacol. 1999; 39: 936-940
        • Prange A.J.
        Estrogen may well affect the response to antidepressants.
        JAMA. 1972; 219: 143-144
        • Rapport D.J.
        • Calabrese J.R.
        Interactions between carbamazepine and birth control pills.
        Psychosomatics. 1989 Fall; 30: 462-464
        • Rietveld E.C.
        • Broekman M.M.M.
        • Houben J.J.G.
        • Eskes T.K.A.B.
        • van Rossum J.M.
        Rapid onset of an increase in caffeine residence time in young women due to oral contraceptive steroids.
        Eur. J. Clin. Pharmacol. 1984; 26: 371-373
        • Roberts R.K.
        • Desmond P.V.
        • Wilkinson G.R.
        • Schenker S.
        Disposition of chlordiazepoxide: sex differences and effects of oral contraceptives.
        Clin. Pharmacol. Ther. 1979 Jun; 25: 826-831
        • Rogers S.M.
        • Back D.J.
        • Stevenson P.J.
        • Grimmer S.F.
        • Orme M.L.
        Paracetamol interaction with oral contraceptive steroids: increased plasma concentrations of ethinyloestradiol.
        Br. J. Clin. Pharmacol. 1987 Jun; 23: 721-725
        • Sabers A.
        • Buchholt J.M.
        • Uldall P.
        • Hansen E.L.
        Lamotrigine plasma levels reduced by oral contraceptives.
        Epilepsy Res. 2001 Nov; 47: 151-154
        • Schrogie J.J.
        • Solomon H.M.
        • Zieve P.D.
        Effect of oral contraceptives on vitamin K-dependent clotting activity.
        Clin. Pharmacol. Ther. 1967 Sep-Oct; 8: 670-675
        • Shelepova T.
        • Nafziger A.N.
        • Victory J.
        • Kashuba A.D.
        • Rowland E.
        • Zhang Y.
        • Sellers E.
        • Kearns G.
        • Leeder J.S.
        • Gaedigk A.
        • Bertino Jr., J.S.
        Effect of a triphasic oral contraceptive on drug-metabolizing enzyme activity as measured by the validated Cooperstown 5+1 cocktail.
        J. Clin. Pharmacol. 2005 Dec; 45: 1413-1421
        • Sinofsky F.E.
        • Pasquale S.A.
        The effect of fluconazole on circulating ethinyl estradiol levels in women taking oral contraceptives.
        Am. J. Obstet. Gynecol. 1998 Feb; 178: 300-304
        • Skolnick J.L.
        • Stoler B.S.
        • Katz D.B.
        • Anderson W.H.
        Rifampin, oral contraceptives, and pregnancy.
        JAMA. 1976 Sep 20; 236: 1382
        • Somani S.M.
        • Khurana R.C.
        Mechanism of estrogen-imipramine interaction.
        JAMA. 1973 Jan 29; 223: 560
        • Sonnen A.E.H.
        Oxcarbazepine and oral contraceptives.
        Acta Neurol. Scand. 1990; 82: 37
        • Stoehr G.P.
        • Kroboth P.D.
        • Juhl R.P.
        • Wender D.B.
        • Phillips J.P.
        • Smith R.B.
        Effect of oral contraceptives on triazolam, temazepam, alprazolam, and lorazepam kinetics.
        Clin. Pharmacol. Ther. 1984 Nov; 36: 683-690
        • Thomson A.W.
        • Bonham C.A.
        • Zeevi A.
        Mode of action of tacrolimus (FK506): molecular and cellular mechanisms.
        Ther. Drug Monit. 1995 Dec; 17: 584-591
        • Tornatore K.M.
        • Kanarkowski R.
        • McCarthy T.L.
        • Gardner M.J.
        • Yurchak A.M.
        • Jusko W.J.
        Effect of chronic oral contraceptive steroids on theophylline disposition.
        Eur. J. Clin. Pharmacol. 1982; 23: 129-134
        • van Puijenbroek E.P.
        • Feenstra J.
        • Meyboom R.H.
        Verstoring van de pilcyclus tijdens het gelijktijdig gebruik van itraconazol en orale anticonceptiva [Pill cycle disturbance in simultaneous use of itraconazole and oral contraceptives].
        Ned. Tijdschr. Geneeskd. 1998 Jan 17; 142: 146-149
        • Veronesi U.
        • Maisonneuve P.
        • Sacchini V.
        • Rotmensz N.
        • Boyle P.
        • Italian Tamoxifen Study Group
        Tamoxifen for breast cancer among hysterectomised women.
        Lancet. 2002 Mar 30; 359: 1122-1124
        • Rees M.
        • Angioli R.
        • Coleman R.L.
        • Glasspool R.
        • Plotti F.
        • Simoncini T.
        • Terranova C.
        European Menopause and Andropause Society (EMAS) and International Gynecologic Cancer Society (IGCS) position statement on managing the menopause after gynecological cancer: focus on menopausal symptoms and osteoporosis.
        Maturitas. 2020; 134: 56-61
        • Neves-E-Castro M.
        • Birkhauser M.
        • Samsioe G.
        • Lambrinoudaki I.
        • Palacios S.
        • Borrego R.S.
        • Llaneza P.
        • Ceausu I.
        • Depypere H.
        • Erel C.T.
        • Pérez-López F.R.
        • Schenck-Gustafsson K.
        • van der Schouw Y.T.
        • Simoncini T.
        • Tremollieres F.
        • Rees M.
        EMAS position statement: The ten point guide to the integral management of menopausal health.
        Maturitas. 2015; 81: 88-92
        • Mendoza N.
        • Juliá M.D.
        • Galliano D.
        • Coronado P.
        • Díaz B.
        • Fontes J.
        • Gallo J.L.
        • García A.
        • Guinot M.
        • Munnamy M.
        • Roca B.
        • Sosa M.
        • Tomás J.
        • Llaneza P.
        • Sánchez-Borrego R.
        Spanish consensus on premature menopause.
        Maturitas. 2015; 80: 220-225